• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer

by Fred Pennic 12/04/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer

What You Should Know:

– Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer.

– This partnership combines Absci’s cutting-edge Integrated Drug Creation™ platform with AstraZeneca’s oncology expertise, aiming to accelerate the discovery of a potential new cancer treatment.

Absci’s AI Engine Takes the Lead

Absci will leverage its innovative AI technology to design a therapeutic antibody against a specific oncology target. AstraZeneca’s upfront commitment, research and development funding, milestone payments, and future royalties on product sales demonstrate their confidence in Absci’s approach.

Revolutionizing Drug Discovery with AI and Wet-Lab Integration

Absci’s Integrated Drug Creation™ platform is a powerful combination of generative AI and cutting-edge wet-lab technologies. It generates proprietary data by analyzing millions of protein-protein interactions, which then trains its AI models. These models are further refined by validating AI-designed antibodies in the real world, creating a continuous feedback loop.

This unique platform accelerates drug discovery by completing the entire cycle of data collection, AI-driven design, and wet-lab validation within an estimated six weeks. It aims to increase the success rate of developing new biologic drugs by optimizing multiple drug features simultaneously and tackling previously “undruggable” targets like GPCRs and ion channels.

The combined expertise of Absci and AstraZeneca offers a promising outlook for developing innovative cancer treatments. By harnessing the power of AI, this collaboration has the potential to significantly accelerate drug discovery and bring new hope to cancer patients worldwide.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Cancer Detection, Cancer Diagnostics, Drug Discovery, Oncology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |